A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice
NCT ID: NCT04053881
Last Updated: 2023-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
412 participants
OBSERVATIONAL
2019-08-21
2022-12-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis
NCT03051217
An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
NCT02326298
A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
NCT02326272
Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)
NCT02346240
A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis
NCT04123795
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Certolizumab pegol
Plaque psoriasis patients who have been newly prescribed certolizumab pegol (CZP).
Certolizumab pegol
Active Substance: Certolizumab Pegol Pharmaceutical Form: Prefilled syringe Concentration: 200 mg/ml Route of Administration: Subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Certolizumab pegol
Active Substance: Certolizumab Pegol Pharmaceutical Form: Prefilled syringe Concentration: 200 mg/ml Route of Administration: Subcutaneous injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient must have a clinical diagnosis of moderate to severe Plaque psoriasis according to the diagnostic criteria used by the physician in routine clinical practice
* The patient has an available PASI assessment prior to the first certolizumab pegol dose according to the standard of care
* The patient must be newly prescribed with certolizumab pegol
* If a patient is participating in an ongoing investigational study, then he/she will not be able to take part in this study
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Biopharma SRL
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Cares
Role: STUDY_DIRECTOR
001 844 599 2273 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ps0026 101
Brussels, , Belgium
Ps0026 103
Brussels, , Belgium
Ps0026 107
Brussels, , Belgium
Ps0026 102
Leuven, , Belgium
Ps0026 110
Maldegem, , Belgium
Ps0026 109
Mons, , Belgium
Ps0026 104
Namur, , Belgium
Ps0026 208
London, , Canada
Ps0026 209
London, , Canada
Ps0026 201
Markham, , Canada
Ps0026 210
Newmarket, , Canada
Ps0026 203
St. John's, , Canada
Ps0026 212
Toronto, , Canada
Ps0026 205
Waterloo, , Canada
Ps0026 204
Winnipeg, , Canada
Ps0026 301
Prague, , Czechia
Ps0026 303
Prague, , Czechia
Ps0026 302
Uherské Hradiště, , Czechia
Ps0026 408
Amiens, , France
Ps0026 404
Lorient, , France
Ps0026 409
Poitiers, , France
Ps0026 403
Rennes, , France
Ps0026 407
Toulon, , France
Ps0026 512
Bielefeld, , Germany
Ps0026 532
Bogen, , Germany
Ps0026 525
Dresden, , Germany
Ps0026 506
Düren, , Germany
Ps0026 521
Freiburg im Breisgau, , Germany
Ps0026 529
Gladbeck, , Germany
Ps0026 523
Hamburg, , Germany
Ps0026 518
Karlsruhe, , Germany
Ps0026 519
Leipzig, , Germany
Ps0026 537
Magdeburg, , Germany
Ps0026 530
Memmingen, , Germany
Ps0026 516
Merzig, , Germany
Ps0026 517
München, , Germany
Ps0026 527
München, , Germany
Ps0026 515
Nuremberg, , Germany
Ps0026 501
Potsdam, , Germany
Ps0026 511
Quedlinburg, , Germany
Ps0026 505
Remscheid, , Germany
Ps0026 603
Athens, , Greece
Ps0026 609
Athens, , Greece
Ps0026 610
Athens, , Greece
Ps0026 601
Chaïdári, , Greece
Ps0026 606
Larissa, , Greece
Ps0026 608
Pátrai, , Greece
Ps0026 607
Piraeus, , Greece
Ps0026 604
Thessaloniki, , Greece
Ps0026 605
Thessaloniki, , Greece
Ps0026 707
Bari, , Italy
Ps0026 714
Bologna, , Italy
Ps0026 711
Brescia, , Italy
Ps0026 712
Catania, , Italy
Ps0026 710
Florence, , Italy
Ps0026 702
Genova, , Italy
Ps0026 706
L’Aquila, , Italy
Ps0026 701
Napoli, , Italy
Ps0026 709
Roma, , Italy
Ps0026 713
Roma, , Italy
Ps0026 704
San Donato Milanese, , Italy
Ps0026 715
Torino, , Italy
Ps0026 708
Torrette DI Ancona, , Italy
Ps0026 807
Badalona, , Spain
Ps0026 809
Barcelona, , Spain
Ps0026 812
Barcelona, , Spain
Ps0026 804
Pontevedra, , Spain
Ps0026 806
Sant Joan Despí, , Spain
Ps0026 818
Vigo, , Spain
Ps0026 902
Bradford, , United Kingdom
Ps0026 909
Dunfermline, , United Kingdom
Ps0026 914
Glasgow, , United Kingdom
Ps0026 916
Hertfordshire, , United Kingdom
Ps0026 911
Kingston upon Thames, , United Kingdom
Ps0026 905
Leeds, , United Kingdom
Ps0026 904
Newcastle upon Tyne, , United Kingdom
Ps0026 901
Salford, , United Kingdom
Ps0026 915
Wakefield, , United Kingdom
Ps0026 908
York, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Korge B, Vanhooteghem O, Lynde CW, Machovcova A, Perrussel M, Lazaridou E, Marasca C, Sarro DV, Pousa ID, Fierens F, Williams P, Shimizu S, Heidbrede T, Warren RB. Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study. Dermatol Ther (Heidelb). 2024 Aug;14(8):2077-2092. doi: 10.1007/s13555-024-01210-3. Epub 2024 Jun 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PS0026
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.